MX2021002611A - Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo. - Google Patents
Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.Info
- Publication number
- MX2021002611A MX2021002611A MX2021002611A MX2021002611A MX2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclodextrin
- compexes
- derivatives
- pharmaceutical composition
- formula
- Prior art date
Links
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005238 anethole trithione Drugs 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862727691P | 2018-09-06 | 2018-09-06 | |
| EP18306172 | 2018-09-06 | ||
| PCT/EP2019/073873 WO2020049166A1 (en) | 2018-09-06 | 2019-09-06 | Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002611A true MX2021002611A (es) | 2021-07-21 |
Family
ID=67841092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002611A MX2021002611A (es) | 2018-09-06 | 2019-09-06 | Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12295969B2 (https=) |
| EP (1) | EP3846856A1 (https=) |
| JP (1) | JP7362725B2 (https=) |
| KR (1) | KR20210054540A (https=) |
| CN (1) | CN113038969A (https=) |
| AU (2) | AU2019336943A1 (https=) |
| BR (1) | BR112021003997A2 (https=) |
| CA (1) | CA3111886A1 (https=) |
| IL (1) | IL281161B2 (https=) |
| MX (1) | MX2021002611A (https=) |
| WO (1) | WO2020049166A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022123038A1 (en) * | 2020-12-10 | 2022-06-16 | OP2 Drugs | Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries |
| EP4112051A1 (en) * | 2021-06-30 | 2023-01-04 | Op2 Drugs | Anethole trithione for the treatment of vasculitides |
| CN114558004B (zh) * | 2022-03-29 | 2023-08-11 | 奎马特里克斯有限公司 | Qtx125药物制剂 |
| CN115738757B (zh) * | 2022-11-24 | 2024-03-29 | 中国海洋大学 | 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262165A (en) | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| CA2222133C (en) | 1995-06-07 | 2002-12-24 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| AU5474198A (en) * | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| CN1771938A (zh) | 2004-11-09 | 2006-05-17 | 胡才忠 | 茴三硫脂质体及其制备方法 |
| JP6876047B2 (ja) * | 2015-09-08 | 2021-05-26 | オーピーツー ドラッグス | ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物 |
| BR112018004518A2 (pt) * | 2015-09-08 | 2019-03-19 | OP2 Drugs | compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais |
| AU2018232799B2 (en) * | 2017-03-07 | 2021-11-25 | Centre Hospitalier Universitaire De Bordeaux | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production |
-
2019
- 2019-09-06 AU AU2019336943A patent/AU2019336943A1/en not_active Abandoned
- 2019-09-06 WO PCT/EP2019/073873 patent/WO2020049166A1/en not_active Ceased
- 2019-09-06 JP JP2021512682A patent/JP7362725B2/ja active Active
- 2019-09-06 EP EP19762427.3A patent/EP3846856A1/en active Pending
- 2019-09-06 IL IL281161A patent/IL281161B2/en unknown
- 2019-09-06 MX MX2021002611A patent/MX2021002611A/es unknown
- 2019-09-06 BR BR112021003997-0A patent/BR112021003997A2/pt unknown
- 2019-09-06 US US17/273,928 patent/US12295969B2/en active Active
- 2019-09-06 KR KR1020217009152A patent/KR20210054540A/ko not_active Ceased
- 2019-09-06 CA CA3111886A patent/CA3111886A1/en active Pending
- 2019-09-06 CN CN201980072663.5A patent/CN113038969A/zh active Pending
-
2025
- 2025-06-03 AU AU2025204144A patent/AU2025204144A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019336943A1 (en) | 2021-03-18 |
| JP2021536472A (ja) | 2021-12-27 |
| IL281161B2 (en) | 2024-01-01 |
| KR20210054540A (ko) | 2021-05-13 |
| IL281161B1 (en) | 2023-09-01 |
| US20210308173A1 (en) | 2021-10-07 |
| BR112021003997A2 (pt) | 2021-05-25 |
| CA3111886A1 (en) | 2020-03-12 |
| IL281161A (en) | 2021-04-29 |
| CN113038969A (zh) | 2021-06-25 |
| AU2025204144A1 (en) | 2025-06-26 |
| EP3846856A1 (en) | 2021-07-14 |
| US12295969B2 (en) | 2025-05-13 |
| JP7362725B2 (ja) | 2023-10-17 |
| WO2020049166A1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002611A (es) | Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo. | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2023000314A (es) | Formulaciones farmaceuticas transdermicas de cannabinoides. | |
| JOP20240124A1 (ar) | مركبات 2-أمينو-3-سيانو ثيوفين حلقية ومشتقاتها لعلاج السرطان | |
| DOP2022000266A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| UA130338C2 (uk) | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування | |
| MX2022006663A (es) | Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| MX2021003655A (es) | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| CY1119488T1 (el) | Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| MX2024001777A (es) | Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| BR0209027A (pt) | Composto ácido carboxìlico e seu uso, medicamento, agente e método para a prevenção ou tratamento de uma doença, composição farmacêutica | |
| WO2023078333A8 (zh) | 一种取代的苯丙酸衍生物及其用途 | |
| NO20085158L (no) | Farmasoytiske blandinger av ropinirol samt deres anvendelse | |
| MX386782B (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| NZ748771A (en) | Pharmaceutical compositions comprising nitroxyl donors | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| MX2025002790A (es) | Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos | |
| EA202091725A1 (ru) | Офтальмические композиции, содержащие биластин, бета-циклодекстрин и по крайней мере одно желатинирующее вещество | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos |